Real-World Experience of Clascoterone Cream 1% in Acne Management: Case Series and Canadian Experience
Bibliographic record
Abstract
Elena Tay,1 Wei Jing Loo1– 3 1Western University, London, ON, Canada; 2DermEffects, London, ON, Canada; 3Probity Medical Research, Waterloo, ON, CanadaCorrespondence: Wei Jing Loo, DermEffects, 1560 Hyde Park Road, London, ON N6H 5L5, Canada, Tel +1 519 472 2929, Email dermeffects@gmail.comAbstract: Acne vulgaris is a globally prevalent dermatological condition associated with substantial physical and psychological burden. Although acne typically presents during adolescence, it is a chronic condition that also affects many adults. Despite the spectrum of treatments available for acne, limitations in tolerability and safety concerns can present challenges for the use of conventional medications in clinical practice. Clascoterone cream 1%, a topical androgen receptor inhibitor, was recently approved in Canada for the topical treatment of acne vulgaris. This case series included 10 patients with acne vulgaris who were treated with clascoterone cream 1% as monotherapy or part of a combination treatment program between August 2023 and May 2024. Clascoterone cream 1% was effective and well tolerated regardless of acne severity, age, gender, and ethnicity. Clascoterone led to clinical improvement when used as monotherapy, adjunctive treatment in combination with other topical or systemic agents or laser therapy, and as maintenance therapy to prevent relapse of acne. Moreover, clascoterone also helped to address other concerns in several patients, including hirsutism, hidradenitis suppurativa, retinoid-induced dermatitis, androgenetic alopecia, folliculitis, postinflammatory hyperpigmentation, and laser-induced acne flares. This early real-world clinical experience supports the effectiveness, tolerability, and versatility of clascoterone cream 1% for patients with acne across a variety of clinical and demographic characteristics.Keywords: androgen, topical, therapy, efficacy, safety, tolerability
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.004 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.001 | 0.002 |
| Science and technology studies | 0.004 | 0.001 |
| Scholarly communication | 0.002 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.002 | 0.002 |
| Insufficient payload (model declined to judge) | 0.003 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".